Germany's IQWiG confirms Jetrea's added value for VMT patients

2 August 2013

Belgian biopharma company ThromboGenics (Euronext Brussels: THR) announced today (August 2) that the German Institute for Quality and Efficiency in Health Care (IQWiG) has confirmed that Jetrea (ocriplasmin) demonstrates major/significant added value in vitreomacular traction (VMT) patients with mild/moderately severe symptoms compared with existing comparative treatment, when treating VMT including when associated with a macular hole of less than or equal to 400 microns.

Jetrea is the first pharmacological treatment indicated for use in patients diagnosed with VMT and macular hole of diameter less than or equal to 400 microns. It was approved for this indication in the European Union in March 2013. Partner Alcon, the eye care unit of Swiss drug major Novartis (NOVN: VX) launched the drug in Germany at the beginning of May. The drug gained backing from the UK equivalent of the IQWiG, the NICE, earlier this year (The Pharma Letter June 12).

Claimed to be only VMT treatment in development

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK